Letter/Communication
Emicizumab: A Promising Option for Hemostatic Control in Acquired Hemophilia A
NEJM journal watch. Oncology & hematology
11/03/2023
Abstract
Emicizumab offers an excellent hemostatic option for control of acute bleeding and subsequent bleeding prophylaxis until inhibitors are eradicated.
Details
- Title: Subtitle
- Emicizumab: A Promising Option for Hemostatic Control in Acquired Hemophilia A
- Creators
- Anjali Sharathkumar
- Resource Type
- Letter/Communication
- Publication Details
- NEJM journal watch. Oncology & hematology
- Publisher
- Massachusetts Medical Society
- ISSN
- 2330-0426
- Language
- English
- Date published
- 11/03/2023
- Academic Unit
- Stead Family Department of Pediatrics; Hematology/Oncology
- Record Identifier
- 9984507025502771
Metrics
1 Record Views